|
You may know what the ABOM is: The Angelman Syndrome Biomarker and Outcome Measure Consortium (ABOM).
But do you know why it matters? Why FAST has invested over $2M into its acceleration?
The ABOM is a consortium that brings together hundreds of members including pharmaceutical companies, clinicians, translational research teams, and patient advocacy groups, in order to advance endpoints and biomarkers, which are required to accurately test drugs in clinical trials.
The ABOM Consortium is made up of a team of over 300 people that have interest in advancing the regulatory science to understand, develop, test and validate different tools that can assess individuals living with Angelman syndrome in a way that can get at what is both meaningful and measurable in their lives.
On July 31, 2022, the steering committee came together in person in Austin, Texas, prior to the Angelman Syndrome Foundation Conference, to ensure that we were advancing these endpoints and aligned on goals, objectives and deliverables for 2022, of which the science and results will be presented in person on December 1, 2022 the day prior to the FAST Global Science Summit.
Read more about ABOM’s mission, structure, and plans for the future:
|